Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Aim To investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin versus dipeptidyl peptidase‐4 (DPP‐4) inhibitor treatment across the broad spectrum of cardiovascular risk. Methods In a population‐based cohort study we identified 39 072 pairs of 1:1 propensity score‐matched adult patients with T2D initiating empagliflozin or DPP‐4 inhibitors, using data from 2 US commercial insurance databases and Medicare between August 2014 and September 2017. The primary outcomes were a composite of myocardial infarction (MI)/stroke, and hospitalization for heart failure (HHF). Safety outcomes were bone fractures, lower‐limb amputations (LLAs), diabetic ketoacidosis (DKA), and acute kidney injury (AKI). We estimated pooled hazard ratios (HRs) and 95% confidence intervals (CIs) adjusting for more than 140 baseline covariates. Results Study participants had a mean age of 60 years and only 28% had established cardiovascular disease. Compared to DPP‐4 inhibitors, empagliflozin was associated with similar risk of MI/stroke (HR 0.99 [95% CI 0.81‐1.21]), and lower risk of HHF (HR 0.48 [95% CI 0.35‐0.67] and 0.63 [95% CI 0.54‐0.74], based on a primary and any heart failure discharge diagnosis, respectively). The HR was 0.52 (95% CI 0.38‐0.72) for all‐cause mortality (ACM) and 0.83 (95% CI 0.70‐0.98) for a composite of MI/stroke/ACM. Empagliflozin was associated with a similar risk of LLA and fractures, an increased risk of DKA (HR 1.71 [95% CI 1.08‐2.71]) and a decreased risk of AKI (HR 0.60 [95% CI 0.43‐0.85]). Conclusions In clinical practice, the initiation of empagliflozin versus a DPP‐4 inhibitor was associated with a lower risk of HHF, ACM and MI/stroke/ACM, a similar risk of MI/stroke, and a safety profile consistent with documented information.